OLIG2 antibody |
|||
| 10R-11198 | Fitzgerald | 100 ug | EUR 418.8 |
|
Description: Mouse Monoclonal OLIG2 antibody |
|||
Goat Antibody Laboratories manufactures the rnd goat olig2 antibody reagents distributed by Genprice. The Rnd Goat Olig2 Antibody reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact goat Antibody. Other Rnd products are available in stock. Specificity: Rnd Category: Goat Group: Olig2 Antibody
OLIG2 Antibody |
||
| Affbiotech | 200ul | EUR 420 |
olig2 Antibody |
||
| Cusabio |
|
|
|
Description: A polyclonal antibody against olig2. Recognizes olig2 from Zebrafish. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
||
OLIG2 Antibody |
||
| Cusabio |
|
|
|
Description: A polyclonal antibody against OLIG2. Recognizes OLIG2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
||
Olig2 Antibody |
||
| NSJ Bioreagents | 0.08 ml | EUR 140.25 |
|
Description: This gene encodes a basic helix-loop-helix transcription factor which is expressed in oligodendroglial tumors of the brain. The protein is an essential regulator of ventral neuroectodermal progenitor cell fate. The gene is involved in a chromosomal translocation t(14;21)(q11.2;q22) associated with T-cell acute lymphoblastic leukemia. Its chromosomal location is within a region of chromosome 21 which has been suggested to play a role in learning deficits associated with Down syndrome. [provided by RefSeq]. |
||
Olig2 Antibody |
||
| NSJ Bioreagents | 0.4 ml | EUR 322.15 |
|
Description: This gene encodes a basic helix-loop-helix transcription factor which is expressed in oligodendroglial tumors of the brain. The protein is an essential regulator of ventral neuroectodermal progenitor cell fate. The gene is involved in a chromosomal translocation t(14;21)(q11.2;q22) associated with T-cell acute lymphoblastic leukemia. Its chromosomal location is within a region of chromosome 21 which has been suggested to play a role in learning deficits associated with Down syndrome. [provided by RefSeq]. |
||
OLIG2 Antibody |
||
| NSJ Bioreagents | 100ug | EUR 349.3 |
|
Description: Olig2, a basic helix loop helix transcription factor, is involved in oligo-dendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue. |
||
OLIG2 Antibody |
||
| NSJ Bioreagents | 20ug | EUR 153.3 |
|
Description: Olig2, a basic helix loop helix transcription factor, is involved in oligo-dendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue. |
||
OLIG2 Antibody |
|||
| V3819-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: Olig2, a basic helix-loop-helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuro-epithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid / rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). |
|||
OLIG2 Antibody |
|||
| V3819SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Olig2, a basic helix-loop-helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuro-epithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid / rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). |
|||
OLIG2 Antibody |
|||
| V3822-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Olig2, a basic helix-loop-helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuro-epithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid / rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). |
|||
OLIG2 Antibody |
|||
| V3822-20UG | NSJ Bioreagents | 20 ug | EUR 153.3 |
|
Description: Olig2, a basic helix-loop-helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuro-epithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid / rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). |
|||
OLIG2 Antibody |
|||
| V3822SAF-100UG | NSJ Bioreagents | 100 ug | EUR 349.3 |
|
Description: Olig2, a basic helix-loop-helix transcription factor, is involved in oligodendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuro-epithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid / rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue (gliosis). |
|||
anti- OLIG2 antibody |
|||
| FNab05986 | FN Test | 100µg | EUR 606.3 |
|
Description: Antibody raised against OLIG2 |
|||
anti- OLIG2 antibody |
|||
| FNab05987 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against OLIG2 |
|||
Polyclonal OLIG2 Antibody |
|||
| AMM06894G | Leading Biology | 0.1 mg | EUR 790.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human OLIG2 . This antibody is tested and proven to work in the following applications: |
|||
Monoclonal OLIG2 Antibody |
|||
| AMM06895G | Leading Biology | 0.1ml | EUR 580.8 |
|
Description: A Monoclonal antibody against Human OLIG2. The antibodies are raised in Mouse. This antibody is applicable in WB |
|||
Polyclonal Olig2 Antibody |
|||
| AMM06896G | Leading Biology | 0.1ml | EUR 633.6 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Olig2 . This antibody is tested and proven to work in the following applications: |
|||
OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400) Antibody |
|||
| BNC942400-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400), CF594 conjugate, Concentration: 0.1mg/mL |
|||
OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400) Antibody |
|||
| BNC942400-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400), CF594 conjugate, Concentration: 0.1mg/mL |
|||
OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400) Antibody |
|||
| BNC802400-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400), CF680 conjugate, Concentration: 0.1mg/mL |
|||
OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400) Antibody |
|||
| BNC802400-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400), CF680 conjugate, Concentration: 0.1mg/mL |
|||
OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400) Antibody |
|||
| BNC702400-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400), CF770 conjugate, Concentration: 0.1mg/mL |
|||
OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400) Antibody |
|||
| BNC702400-500 | Biotium | 500uL | EUR 654 |
|
Description: Primary antibody against OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400), CF770 conjugate, Concentration: 0.1mg/mL |
|||
OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400) Antibody |
|||
| BNC882400-100 | Biotium | 100uL | EUR 279.6 |
|
Description: Primary antibody against OLIG2 (Marker of Glial Brain Tumors) (OLIG2/2400), CF488A conjugate, Concentration: 0.1mg/mL |
|||